Immunotherapy for Lung Cancer
Immunotherapy for Lung Cancer
复制标题
DOI：
10.37047/jos.2022-92712
复制
发表时间：
2023
影响因子：
--
通讯作者：
N. Karadurmuş;N. Akyürek;A. Aydıner;R. Savaş;Özlem Sönmez;M. Şendur;B. Oyan;D. Yalman;Mehmet Ufuk Yilmaz;Ülkü Yılmaz;P. Yumuk;E. Göker
中科院分区：
文献类型：
--
作者：
N. Karadurmuş;N. Akyürek;A. Aydıner;R. Savaş;Özlem Sönmez;M. Şendur;B. Oyan;D. Yalman;Mehmet Ufuk Yilmaz;Ülkü Yılmaz;P. Yumuk;E. Göker
ABS TRACT 肺癌是男性和女性癌症相关死亡的主要原因之一。与其他癌症类型的方法类似，肺癌分期对于规划有效的治疗计划和预测患者预后至关重要。针对非小细胞肺癌和非基因组驱动突变患者的有效免疫疗法正在迅速发展。此外，基于抗程序性死亡受体 1 (PD-1)/程序性死亡配体 1 (PD-L1) 的治疗已成为一线治疗标准。尽管存在缺陷，PD-L1 表达水平目前似乎是抗 PD-1/PD-L1 抗体治疗临床疗效的相对可靠的预测因子。然而，需要额外的生物标志物来更好地为这些患者提供个性化的治疗选择。本综述旨在提高对肺癌和免疫疗法治疗选择的认识，具体取决于患者和疾病阶段特征。
ABS TRACT Lung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death receptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 antibodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics.